Butorphanol dependence and withdrawal decrease hippocampal κ2-opioid receptor binding

Brain Research

Volumn 958, Issue 2, 2002, Pages 277-290

  Fan, Lir Wan ^a   Tanaka, Sachiko ^b   Park, Younjoo ^c   Sasaki, Kenro ^a   Ma, Tangeng ^a   Tien, Lu Tai ^a   Rockhold, Robin William ^a   Ho, Ing Kang ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b SHOWA UNIVERSITY   (Japan)

^c National Institute of Toxicological Research   (South Korea)

Author keywords

2 Opioid receptor; Autoradiography; Butorphanol dependence; Butorphanol withdrawal

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BREMAZOCINE; BUTORPHANOL; ENADOLINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG INFUSION; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; LOCUS CERULEUS; MALE; MOLECULAR BIOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECEPTOR BINDING; TEGMENTUM;

ANIMALS; BUTORPHANOL; HIPPOCAMPUS; MALE; OPIOID-RELATED DISORDERS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0037184684     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03572-2     Document Type: Article

References (84)

1. Bernstein M.A., Welch S.P. mu-Opioid receptor down-regulation and cAMP-dependent protein kinase phosphorylation in a mouse model of chronic morphine tolerance. Mol. Brain Res. 55:1998;237-242.
2. 3H]-CI-977: A highly selective ligand for the κ-opioid receptor in both guinea-pig and rat forebrain. Mol. Neuropharmacol. 1:1990;23-29.
3. Brown G.R. Stadol dependence: another case. J. Am. Med. Assoc. 254:1985;910.
4. Castillo P.E., Salin P.A., Weisskopf M.G., Nicoll R.A. Characterizing the site and mode of action of dynorphin at hippocampal mossy fiber synapses in the guinea pig. J. Neurosci. 16:1996;5942-5950.
5. Caudle R.M., Finegold A.A., Mannes A.J., Tobias M.D., Kenshalo D.R. Jr., Iadarola M.J. Spinal kappa1 and kappa2 opioid binding sites in rats, guinea pigs, monkeys and humans. Neuroreport. 9:1998;2523-2525.
6. Caudle R.M., Mannes A.J., Iadarola M.J. GR89,696 is a kappa-2 opioid receptor agonist and a kappa-1 opioid receptor antagonist in the guinea pig hippocampus. J. Pharmacol. Exp. Ther. 283:1997;1342-1349.
7. Caudle R.M., Chavkin C., Dubner R. Kappa 2 opioid receptors inhibit NMDA receptor-mediated synaptic currents in guinea pig CA3 pyramidal cells. J. Neurosci. 14:1994;5580-5589.
8. Chang K.J., Wei E.T., Killian A., Chang J.K. Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J. Pharmacol. Exp. Ther. 227:1983;403-408.
9. Christie M.J., Williams J.T., Osborne P.B., Bellchambers C.E. Where is the locus in opioid withdrawal? Trends Pharmacol. Sci. 18:1997;134-140.
10. Collins S., Altschmied J., Herbsman O., Caron M.G., Mellon P.L., Lefkowitz R.J. A cAMP response element in the beta 2-adrenergic receptor gene confers transcriptional autoregulation by cAMP. J. Biol. Chem. 265:1990;19330-19335.
11. Devine D.P., Wise R.A. Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J. Neurosci. 14:1994;1978-1984.
12. Dobkin A.B., Arandia H.Y., Byles P.H., Africa B.F., Caruso F.S., Noveck R.J. Butorphanol tartrate: 2. Safety and efficacy in balanced anaesthesia. Can. Anaesth. Soc. J. 23:1976;601-608.
13. Drake C.T., Patterson T.A., Simmons M.L., Chavkin C., Milner T.A. Kappa opioid receptor-like immunoreactivity in guinea pig brain: Ultrastructural localization in presynaptic terminals in hippocampal formation. J. Comp. Neurol. 370:1996;377-395.
14. Evans W.S., Bowen J.N., Giordano F.L., Clark B. A case of stadol dependence. J. Am. Med. Assoc. 253:1985;2191-2192.
15. 1-opioid receptor binding in the rat brain. Brain Res. Bull. 58:2002;149-160.
16. Feng Y.Z., Tseng Y.T., Jaw S.P., Hoskins B., Ho I.K. Tolerance development to butorphanol: comparison with morphine. Pharmacol. Biochem. Behav. 49:1994;649-655.
17. Feng Y.Z., Zhang T., Rockhold R.W., Ho I.K. Increased locus coeruleus glutamate levels are associated with naloxone-precipitated withdrawal from butorphanol in the rat. Neurochem. Res. 20:1995;745-751.
18. Feng Y.Z., Rockhold R.W., Ho I.K. Nor-binaltorphimine precipitates withdrawal and excitatory amino acid release in the locus coeruleus of butorphanol but not morphine-dependent rats. J. Pharmacol. Exp. Ther. 283:1997;932-938.
19. Fisher M.A., Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology. 48:1997;1156-1160.
20. Goodman R.H. Regulation of neuropeptide gene expression. Annu. Rev. Neurosci. 13:1990;111-127.
21. Guitart X., Thompson M.A., Mirante C.K., Greenberg M.E., Nestler E.J. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. J. Neurochem. 58:1992;1168-1171.
22. Ho I.K., Feng Y.Z., Tokuyama S., Hoshi K., Rockhold R.W. Glutamate in opioid dependence. Nihon Shinkei Seishin Yakurigaku Zasshi. 17:1997;175-180.
23. Ho J., Mannes A.J., Dubner R., Caudle R.M. Putative kappa-2 opioid agonists are antihyperalgesic in a rat model of inflammation. J. Pharmacol. Exp. Ther. 281:1997;136-141.
24. Horan P., Ho I.K. The physical dependence liability of butorphanol: A comparative study with morphine. Eur. J. Pharmacol. 203:1991;387-391.
25. Hoshi K., Ma T., Oh S., Ho I.K. Increased release of excitatory amino acids in rat locus coeruleus in kappa-opioid agonist dependent rats precipitated by nor-binaltorphimine. Brain Res. 753:1997;63-68.
26. 3H]MK-801 binding during butorphanol withdrawal in the rat brain. Brain Res. 845:1999;236-241.
27. 3H]forskolin to adenylate cyclase. Brain Res. 821:1999;520-525.
28. Jaw S.P., Hoskinsn B., Ho I.K. Involvement of delta-opioid receptors in physical dependence on butorphanol. Eur. J. Pharmacol. 240:1993;67-72.
29. Jaw S.P., Hoskinsn B., Ho I.K. Opioid antagonists and butorphanol dependence. Pharmacol. Biochem. Behav. 44:1993;497-500.
30. Jaw S.P., Makimura M., Hoskins B., Ho I.K. Effects of nor-binaltorphimine on butorphanol dependence. Eur. J. Pharmacol. 239:1993;133-140.
31. Jaw S.P., Makimura M., Oh K.W., Hoskins B., Ho I.K. Involvement of kappa-opioid receptors in opioid dependence/withdrawal: studies using butorphanol. Eur. J. Pharmacol. 257:1994;153-160.
32. Jordan B.A., Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 399:1999;697-700.
33. Kitchen I., Slowe S.J., Matthes H.W., Kieffer B. Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res. 778:1997;73-88.
34. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
35. Koob G.F., Maldonado R., Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci. 15:1992;186-191.
36. 3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur. J. Pharmacol. 109:1985;281-284.
37. Law P.Y., Loh H.H. Regulation of opioid receptor activities. J. Pharmacol. Exp. Ther. 289:1999;607-624.
38. Li J., Li J.G., Chen C., Zhang F., Liu-Chen L.Y. Molecular basis of differences in (-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)-cyclohexyl] benzeneacetamide-induced desensitization and phosphorylation between human and rat kappa-opioid receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 61:2002;73-84.
39. Li J.G., Benovic J.L., Liu-Chen L.Y. Mechanisms of agonist-induced down-regulation of the human κ-opioid receptor: Internalization is required for down-regulation. Mol. Pharmacol. 58:2000;795-801.
40. Liu N., Rockhold R.W., Ho I.K. Electrical stimulation of nucleus paragigantocellularis induces opioid withdrawal-like behaviors in the rats. Pharmacol. Biochem. Behav. 62:1999;263-271.
41. m GTPase activity in rat brain: evidence for the involvement of G-proteins in opioid tolerance. Brain Res. Bull. 38:1995;565-568.
42. Maldonado R., Blendy J.A., Tzavara E., Gass P., Roques B.P., Hanoune J., Schutz G. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science. 273:1996;657-659.
43. Maldonado R., Stinus L., Gold H., Koob G.F. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261:1992;669-677.
44. Mamoon A.M., Barnes A.M., Ho I.K., Hoskins B. Comparative rewarding properties of morphine and butorphanol. Brain Res. Bull. 38:1995;507-511.
45. Mansour A., Hoversten M.T., Taylor L.P., Watson S.J., Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain. Res. 700:1995;89-98.
46. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7:1987;2445-2464.
47. Meng F., Xie G.X., Thompson R.C., Mansour A., Goldstein A., Watson S.J., Akil H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc. Natl. Acad. Sci. USA. 90:1993;9954-9958.
48. Minami M., Toya T., Katao Y., Maekawa K., Nakamura S., Onogi T., Kaneko S., Satoh M. Cloning and expression of a cDNA for the rat kappa-opioid receptor. FEBS Lett. 329:1993;291-295.
49. Montminy M.R., Gonzalez G.A., Yamamoto K.K. Regulation on cAMP-inducible genes by CREB. Trends Neurosci. 13:1990;184-188.
50. Mulder A.B., Hodenpijl M.G., Lopes da Silva F.H. Electrophysiology of the hippocampal and amygdaloid projections to the nucleus accumbens of the rat: convergence, segregation, and interaction of inputs. J. Neurosci. 18:1998;5095-5102.
51. Narita M., Feng Y., Makimura M., Hoskins B., Ho I.K. A protein kinase inhibitor, H-7, inhibits the development of tolerance to opioid antinociception. Eur. J. Pharmacol. 271:1994;543-545.
52. Nestler E.J. Molecular mechanisms of opiate and cocaine addiction. Curr. Opin. Neurobiol. 7:1997;713-719.
53. Nock B., Giordano A.L., Cicero T.J., O'Connor L.H. Affinity of drugs and peptides for U-69,593-sensitive and -insensitive kappa opiate binding sites: the U-69,593-insensitive site appears to be the beta endorphin-specific epsilon receptor. J. Pharmacol. Exp. Ther. 254:1990;412-419.
54. 3H]U-69593 biding sites in rat brain: evidence for kappa opioid receptor subtypes. Eur. J. Pharmacol. 154:1988;27-34.
55. Oh S., Kim J.I., Chung M.W., Ho I.K. Modulation of NMDA receptor subunit mRNA in butorphanol-tolerant and -withdrawing rats. Neurochem. Res. 25:2000;1603-1611.
56. 35S]GTPgammaS binding in butorphanol continuously infused rat. Brain Res. Bull. 52:2000;17-20.
57. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th Edition :1998;Academic Press, San Diego, CA.
58. Peachey J.E. Clinical observations of agonist-antagonist analgesic dependence. Drug Alcohol Depend. 20:1987;347-365.
59. Pircio A.W., Gylys J.A., Cavanagh R.L., Buyniski J.P., Bierwagen M.E. The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic. Arch. Int. Pharmacodyn. Ther. 220:1976;231-257.
60. 35S]guanylyl-5′-O-(gamma-thio)-triphosphate binding in human frontal cortex and cerebellum. Neurosci. Lett. 283:2000;213-216.
61. Rockhold R.W., Liu N., Coleman D., Commiskey S., Shook J., Ho I.K. The nucleus paragigantocellularis and opioid withdrawal-like behavior. J. Biomed. Sci. 7:2000;270-276.
62. Schmidt P., Schmolke C., Musshoff F., Prohaska C., Menzen M., Madea B. Numerical density of mu opioid receptor expressing neurons in the frontal cortex of drug related fatalities. Forensic. Sci. Int. 115:2001;219-229.
63. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18:1995;463-495.
64. 2+-regulated transcription factor phosphorylated by calmodulin-dependent kinase. Science. 252:1991;802-808.
65. Shuster S.J., Riedl M., Li X., Vulchanova L., Elde R. Stimulus-dependent translocation of kappa opioid receptors to the plasma membrane. J. Neurosci. 19:1999;2658-2664.
66. Shuster S.J., Riedl M., Li X., Vulchanova L., Elde R. The kappa opioid receptor and dynorphin co-localize in vasopressin magnocellular neurosecretory neurons in guinea-pig hypothalamus. Neuroscience. 96:2000;373-383.
67. Smith S.G., Davis W.M. Nonmedical use of butorphanol and diphenhydramine. J. Am. Med. Assoc. 252:1984;1010.
68. Tao P.L., Han K.F., Wang S.D., Lue W.M., Elde R., Law P.Y., Loh H.H. Immunohistochemical evidence of down-regulation of mu-opioid receptor after chronic PL-017 in rats. Eur. J. Pharmacol. 344:1998;137-142.
69. Tokuyama S., Feng Y.Z., Wakabayashi H., Ho I.K. Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8. Eur. J. Pharmacol. 284:1995;101-107.
70. 2+ channel blocker, on naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats. Psychopharmacology (Berl). 125:1996;135-140.
71. 2+ channel blocker, on naloxone-increased glutamate levels in the locus coeruleus of opioid-dependent rats. Brain Res. 722:1996;212-216.
72. Tokuyama S., Wakabayashi H., Ho I.K. Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur. J. Pharmacol. 295:1996;123-129.
73. Turvhan J., Przewlocka B., Toth G., Lason W., Borsodi A., Przewlocki R. The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience. 91:1999;971-977.
74. Unterwald E.M., Knapp C., Zukin R.S. Neuroanatomical localization of kappa 1 and kappa 2 opioid receptors in rat and guinea pig brain. Brain Res. 562:1991;57-65.
75. Weisskopf M.G., Zalutsky R.A., Nicoll R.A. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation. Nature. 365:1993;188.
76. Werling L.L., McMahon P.N., Cox B.M. Selective changes in mu opioid receptor properties induced by chronic morphine exposure. Proc. Natl. Acad. Sci. USA. 86:1989;6393-6397.
77. Williams J.T., Christie M.J., Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81:2001;299-343.
78. Wise R.A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 19:1996;319-340.
79. Wongchanapai W., Tsang B.K., He Z., Ma T., Ho I.K. Supersensitivity of spinal opioid receptors to antagonists in intrathecal butorphanol and morphine dependence. Life Sci. 63:1998;2175-2180.
80. Woods J.H., Gmerek D.E. Substitution and primary dependence studies in animals. Drug Alcohol Depend. 14:1985;233-247.
81. Zhao B.G., Chapman C., Bicknell R.J. Functional kappa-opioid receptors on oxytocin and vasopressin nerve terminals isolated from the rat neurohypophysis. Brain Res. 462:1988;62-66.
82. Zhu H., Rockhold R.W., Ho I.K. The role of glutamate in physical dependence on opioids. Jpn. J. Pharmacol. 76:1998;1-14.
83. Zhu J., Luo L.Y., Mao G.F., Ashby B., Liu-Chen L.Y. Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 285:1998;28-36.
84. Zukin R.S., Eghbali M., Olive D., Unterwald E.M., Tempel A. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. Proc. Natl. Acad. Sci. USA. 85:1988;4061-4065.